Cargando…
Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 1...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578121/ https://www.ncbi.nlm.nih.gov/pubmed/28786963 http://dx.doi.org/10.3390/ijms18081731 |
_version_ | 1783260474097270784 |
---|---|
author | Noro, Daisuke Yoneyama, Tohru Hatakeyama, Shingo Tobisawa, Yuki Mori, Kazuyuki Hashimoto, Yasuhiro Koie, Takuya Tanaka, Masakazu Nishimura, Shin-Ichiro Sasaki, Hideo Saito, Mitsuru Harada, Hiroshi Chikaraishi, Tatsuya Ishida, Hideki Tanabe, Kazunari Satoh, Shigeru Ohyama, Chikara |
author_facet | Noro, Daisuke Yoneyama, Tohru Hatakeyama, Shingo Tobisawa, Yuki Mori, Kazuyuki Hashimoto, Yasuhiro Koie, Takuya Tanaka, Masakazu Nishimura, Shin-Ichiro Sasaki, Hideo Saito, Mitsuru Harada, Hiroshi Chikaraishi, Tatsuya Ishida, Hideki Tanabe, Kazunari Satoh, Shigeru Ohyama, Chikara |
author_sort | Noro, Daisuke |
collection | PubMed |
description | We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 197 LKTx recipients of whom 16 recipients had ABMR with or without T-cell-mediated rejection (TCMR), 40 recipients had TCMR, and 141 recipients had no adverse events. Multivariate discriminant analysis for prediction of ABMR was performed by inputting an ABMR event as an explanatory variable and sex, age, and serum N-glycan level as objective variables. The N-glycan score was calculated by multiplying the level of candidate objective variables by objective function values. The ABMR predictive performance of the N-glycan score was assessed by receiver operator characteristic curve and Kaplan–Meier curve analyses. The N-glycan score discriminated ABMR with 81.25% sensitivity, 87.85% specificity, and an area under the curve (AUC) of 0.892 that was far superior to that of preformed donor-specific antibody status (AUC, 0.761). Recipients with N-glycan-positive scores >0.8770 had significantly shorter ABMR survival than that of recipients with N-glycan-negative scores. Although the limitations of our study includ its small sample size and retrospective nature, the serum N-glycan score may contribute to prediction of ABMR. |
format | Online Article Text |
id | pubmed-5578121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55781212017-09-05 Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant Noro, Daisuke Yoneyama, Tohru Hatakeyama, Shingo Tobisawa, Yuki Mori, Kazuyuki Hashimoto, Yasuhiro Koie, Takuya Tanaka, Masakazu Nishimura, Shin-Ichiro Sasaki, Hideo Saito, Mitsuru Harada, Hiroshi Chikaraishi, Tatsuya Ishida, Hideki Tanabe, Kazunari Satoh, Shigeru Ohyama, Chikara Int J Mol Sci Article We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 197 LKTx recipients of whom 16 recipients had ABMR with or without T-cell-mediated rejection (TCMR), 40 recipients had TCMR, and 141 recipients had no adverse events. Multivariate discriminant analysis for prediction of ABMR was performed by inputting an ABMR event as an explanatory variable and sex, age, and serum N-glycan level as objective variables. The N-glycan score was calculated by multiplying the level of candidate objective variables by objective function values. The ABMR predictive performance of the N-glycan score was assessed by receiver operator characteristic curve and Kaplan–Meier curve analyses. The N-glycan score discriminated ABMR with 81.25% sensitivity, 87.85% specificity, and an area under the curve (AUC) of 0.892 that was far superior to that of preformed donor-specific antibody status (AUC, 0.761). Recipients with N-glycan-positive scores >0.8770 had significantly shorter ABMR survival than that of recipients with N-glycan-negative scores. Although the limitations of our study includ its small sample size and retrospective nature, the serum N-glycan score may contribute to prediction of ABMR. MDPI 2017-08-08 /pmc/articles/PMC5578121/ /pubmed/28786963 http://dx.doi.org/10.3390/ijms18081731 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Noro, Daisuke Yoneyama, Tohru Hatakeyama, Shingo Tobisawa, Yuki Mori, Kazuyuki Hashimoto, Yasuhiro Koie, Takuya Tanaka, Masakazu Nishimura, Shin-Ichiro Sasaki, Hideo Saito, Mitsuru Harada, Hiroshi Chikaraishi, Tatsuya Ishida, Hideki Tanabe, Kazunari Satoh, Shigeru Ohyama, Chikara Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title_full | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title_fullStr | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title_full_unstemmed | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title_short | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant |
title_sort | serum aberrant n-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578121/ https://www.ncbi.nlm.nih.gov/pubmed/28786963 http://dx.doi.org/10.3390/ijms18081731 |
work_keys_str_mv | AT norodaisuke serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT yoneyamatohru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT hatakeyamashingo serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT tobisawayuki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT morikazuyuki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT hashimotoyasuhiro serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT koietakuya serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT tanakamasakazu serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT nishimurashinichiro serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT sasakihideo serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT saitomitsuru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT haradahiroshi serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT chikaraishitatsuya serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT ishidahideki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT tanabekazunari serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT satohshigeru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant AT ohyamachikara serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant |